Therefore, direct anti-tumor effects of ApoA1 or ApoA1-mimetic peptides may be restricted to tumors that do not overexpress SR-B1; although SR-B1 overexpression in tumors could be exploited by strategies that encapsulate chemotherapeutic agents like DOX in HDL based nanoparticles (see previous section), which may be readily and preferentially taken up by tumor cells overexpressing SR-B1. Here, APOA1 is linked to neoplasm.